Evergreen Youth Secrets
  • Health News
  • Health Care
  • Staying Healthy
  • Beauty Advices
  • Health News
  • Health Care
  • Staying Healthy
  • Beauty Advices
No Result
View All Result
Evergreen Youth Secrets
No Result
View All Result
Home Health Care

Novo Nordisk slashes Wegovy prices through direct-to-consumer pharmacy

by
March 5, 2025
in Health Care
0
Novo Nordisk slashes Wegovy prices through direct-to-consumer pharmacy

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight loss product Wegovy at a significantly reduced cost.

The drugmaker has named its new program NovoCare® Pharmacy, which will sell all dose strengths of Wegovy at $499 per month. According to the company, about 90 percent most patients pay a monthly copay of zero to $25 and this new program is aimed at eligible people who are uninsured or are on insurance plans that don’t cover obesity medicines.

The list price for one month’s supply of Wegovy is $1,349.

“NovoCare® Pharmacy expands the company’s toolkit of offerings to meet the diverse needs of people living with obesity,” the company said in a press release, noting this announcement comes on the heels of the Food and Drug Administration (FDA) recently confirming that both Wegovy and Ozempic, forms of the GLP-1 medication semaglutide, are no longer in shortage.

Wegovy is a form of semaglutide indicated specifically for weight loss. One group of insured individuals who may not be able to access it are Medicare beneficiaries as the federal insurance program is still currently prohibited from covering weight loss drugs. Medicare enrollees can receive coverage for the medication if it is prescribed for its other indication, the reduced risk of cardiovascular death, heart attack and stroke.

While Wegovy and Ozempic were both listed on the FDA’s drug shortage list, compounding pharmacies were able to sell copycat versions of semaglutide at a significantly reduced price. These products were not FDA-approved and as such were not covered by insurers.

The agency’s guidelines do provide some time for patients who were using compounded drugs to transition to the FDA-approved versions of the drugs and this new program from Novo Nordisk appears to cater to individuals who were accustomed to getting semaglutide at a reduced rate without insurance.

The cost of compounded versions of semaglutide sold by online telehealth providers ranged from $150 to $280 for a month’s supply.

“Novo Nordisk continues to advance solutions for patients that improve affordability and access to our medicines, whether they have insurance or not. Today, over 55 million people in the U.S. have coverage specifically for weight management medicines, and 90% of Wegovy® patients with coverage pay $0 to $25 a month for Wegovy®,” said Dave Moore, president of Novo Nordisk Inc.

Eli Lilly, the manufacturer of the GLP-1 drug tirzepatide, similarly made a move last year to offer its in-demand drug at a reduced cost by providing an option of buying it in single-dose vials instead of in autoinjectors.

Previous Post

Freedom Caucus vows quick censure resolution against Al Green

Next Post

Republicans need to cut Medicaid to hit budget savings target, CBO finds

Next Post
Republicans need to cut Medicaid to hit budget savings target, CBO finds

Republicans need to cut Medicaid to hit budget savings target, CBO finds

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

    Popular News

    Trump demands drugmakers ‘justify’ COVID treatment success

    Trump demands drugmakers ‘justify’ COVID treatment success

    September 1, 2025
    Former CDC directors sound alarm over Kennedy’s agency shake-up

    Former CDC directors sound alarm over Kennedy’s agency shake-up

    September 1, 2025
    Candida auris: Study reveals who is most vulnerable to deadly fungus infection

    Candida auris: Study reveals who is most vulnerable to deadly fungus infection

    September 1, 2025

    Trending

    RFK Jr. expected to cut roughly 10K HHS jobs

    RFK Jr. expected to cut roughly 10K HHS jobs

    March 27, 2025
    WHO defends global health, security role after Trump withdrawal

    WHO defends global health, security role after Trump withdrawal

    January 21, 2025
    Trump threatens pharma tariffs of up to 250 percent

    Trump threatens pharma tariffs of up to 250 percent

    August 5, 2025
    FDA approves this season’s Moderna, Pfizer COVID-19 vaccines

    FDA approves this season’s Moderna, Pfizer COVID-19 vaccines

    August 22, 2024

    Recent News

    Trump demands drugmakers ‘justify’ COVID treatment success

    Trump demands drugmakers ‘justify’ COVID treatment success

    September 1, 2025
    Former CDC directors sound alarm over Kennedy’s agency shake-up

    Former CDC directors sound alarm over Kennedy’s agency shake-up

    September 1, 2025

    Popular News

    • Trump demands drugmakers ‘justify’ COVID treatment success
    • Former CDC directors sound alarm over Kennedy’s agency shake-up

    About Evergreen Youth Secrets

    • Contact us
    • Privacy Policy
    • Terms & Conditions
    • Email Whitelisting

    Copyright © 2025 Evergreenyouthsecrets.com. All Rights Reserved.

    No Result
    View All Result
    • Health News
    • Health Care
    • Staying Healthy
    • Beauty Advices

    Copyright © 2025 Evergreenyouthsecrets.com. All Rights Reserved.